Vancouver, BC – July 7, 2021 â Optimi Health Corp. (OTCQB: OPTHF) (CSE: OPTI) (FRA: 8BN) (âOptimiâ or the âCompanyâ), a vertically integrated developer of mushroom products announced today that it has engaged the consulting services of Donohoe Advisory Associates LLC (âDonohoe Advisoryâ) to explore strategies to advance towards a potential Nasdaq listing.
Donohoe Advisory (www.donohoeadvisory.com), which provides listing related consulting services to public companies and law firms, was formed in 2004 by David A. Donohoe, Jr., former Chief Counsel for the Listing Qualifications Department of The Nasdaq Stock Market. Mr. Donohoe is joined by four ex-Nasdaq and NYSE staff members.
âWe welcome the opportunity to work with Optimi,â notes Mr. Donohoe. âItâs a new, exciting and active sector and there are several industry peers which have achieved senior exchange listing with notable success. We believe Optimiâs fundamental approach, business model and early-stage success can pave the way forward to achieve their market ambitions.â
Optimi Healthâs CEO Mike Stier states, âWe have long felt that Optimi presents a business combination that could achieve a senior listing. With todayâs announcement we have begun the next major step towards that goal and are excited by the possibilities ahead.â
On Behalf of the Board of Directors, Optimi Health Corp.
Mike Stier
President, Chief Executive Officer and Director
ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealerâs license under Canadaâs Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.
Find out more at: https://optimihealth.ca/.
FOR FURTHER INFORMATION CONTACT:
Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
FORWARDâLOOKING STATEMENTS
This news release contains forwardâlooking statements and forwardâlooking information within the meaning of Canadian securities legislation (collectively, “forwardâlooking statements”) that relate to Optimiâs current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forwardâlooking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forwardâlooking statements. No assurance can be given that these expectations will prove to be correct and such forwardâlooking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forwardâ looking statements pertaining to the Companyâs potential Nasdaq listing, the dealerâs license application, activities proposed to be conducted under the Companyâs research exemption and associated business related to Psilocybin and Psilocin and Optimiâs plans, focus and objectives.
Forwardâlooking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimiâs control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forwardâlooking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVIDâ19 pandemic and other factors set forth under âForwardâLooking Statements” and âRisk Factorsâ in the Companyâs Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forwardâlooking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forwardâlooking statement. Any forwardâlooking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE: Optimi Health Corp
